Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) – in mice.

None © Shutterstock

In a collaborative effort between the Jenner Institute and the Kennedy Institute of Rheumatology at the University of Oxford, with colleagues in the University of Bern, and the Latvian Biomedical Research & Study Centre, scientists have developed and tested a vaccine that could be used to treat chronic pain caused by osteoarthritis, by blocking the cause of the pain – NGF.

The researchers developed a virus-like particle vaccine that triggers the immune system to produce antibodies to block naturally-occurring NGF. The new vaccine was tested in mice that had signs of painful OA (uneven distribution of weight across the hind legs), and it was shown to visibly reverse these effects.

Read more (University of Oxford website)

Similar stories

Urgent need for COVID-19 vaccine equity: UN-Oxford research

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.

Difficulty hearing speech could be a risk factor for dementia

A new study led by University of Oxford researchers on over 82,000 participants has shown that difficulty hearing spoken conversations is associated with up to 91% increased risk of dementia.

Red and processed meat linked to increased risk of heart disease, Oxford study shows

Largest review of all large-scale studies to date finds red and processed meat increase the risk of heart disease.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues in the Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine) report the unequal impacts of public health measures, and the prevalence of ‘fake news’.